FcγRIIB as a key determinant of agonistic antibody efficacy

Current Topics in Microbiology and Immunology

Volumn 382, Issue , 2014, Pages 355-372

  White, Ann L ^a   Beers, Stephen A ^a   Cragg, Mark S ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Antibodies; Fc receptors; Fc RIIB; Immunotherapy

Indexed keywords

CD40 ANTIGEN; FC RECEPTOR IIB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT; CD27 MONOCLONAL ANTIBODY; CD40 LIGAND MONOCLONAL ANTIBODY; IPILIMUMAB; NIVOLUMAB; RITUXIMAB; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; BINDING AFFINITY; BINDING SITE; DOWN REGULATION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CROSS LINKING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; COMPARATIVE EFFECTIVENESS; EVIDENCE BASED MEDICINE; GENE DELETION; IMMUNOSTIMULATION; PROCESS OPTIMIZATION; PROTEIN INTERACTION; PROTEIN METABOLISM; PROTEIN PROCESSING;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOTHERAPY; RECEPTORS, IGG;

EID: 84958532861     PISSN: 0070217X     EISSN: 21969965     Source Type: Book Series    
DOI: 10.1007/978-3-319-07911-0_16     Document Type: Review

References (89)

1. Ashkenazi A (2002) Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2:420-430
2. Banchereau J, de Paoli P, Valle A, Garcia E, Rousset F (1991) Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. Science 251:70-72
3. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W et al (2011) CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331:1612-1616
4. Beers SA, French RR, Chan CH, Lim SH, Jarrett TC, Vidal RM et al (2010) Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 115:5191-5201
5. Bolland S, Pearse RN, Kurosaki T, Ravetch JV (1998) SHIP modulates immune receptor responses by regulating membrane association of Btk. Immunity 8:509-516
6. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465
7. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S et al (2009) Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113:3716-3725
8. Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA et al (2013) Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptortargeting antibodies. J Exp Med 210:1685-1693
9. Burris H, Ansell S, Nemunaitis J, Weiss G, Sikic B, Northfelt D, Pilja L, Davis T, Yellin M, Keler T, Bullock T (2013) A phase I study of an agonist anti-CD27 human antibody (CDX- 1127) in patients with advanced hematologic malignancies or solid tumors. poster; society for immunotherapy of cancer 28th annual meeting national harbor, MD, USA, 8-10 November 2013
10. Chuntharapai A, Dodge K, Grimmer K, Schroeder K, Marsters SA, Koeppen H et al (2001) Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol 166:4891-4898
11. Clark EA, Ledbetter JA (1986) Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc Natl Acad Sci U S A 83:4494-4498
12. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443-446
13. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ (2005) The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 8:140-174
14. Daéron M, Lesourne R (2006) Negative signaling in Fc receptor complexes. Adv Immunol 89:39-86
15. Daeron M, Latour S, Malbec O, Espinosa E, Pina P, Pasmans S et al (1995) The same tyrosinebased inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity 3:635-646
16. de Haij S, Jansen JH, Boross P, Beurskens FJ, Bakema JE, Bos DL et al (2010) In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res 70:3209-3217
17. Desai DD, Harbers SO, Flores M, Colonna L, Downie MP, Bergtold A et al (2007) Fc{gamma} receptor IIB on dendritic cells enforces peripheral tolerance by inhibiting effector T cell responses. J Immunol 178:6217-6226
18. Dullforce P, Sutton DC, Heath AW (1998) Enhancement of T cell-independent immune responses in vivo by CD40 antibodies. Nat Med 4:88-91
19. Eliopoulos AG, Young LS (2004) The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 4:360-367
20. Enyedy EJ, Mitchell JP, Nambiar MP, Tsokos GC (2001) Defective FcgammaRIIb1 signaling contributes to enhanced calcium response in B cells from patients with systemic lupus erythematosus. Clin Immunol 101:130-135
21. Ferrara C, Stuart F, Sondermann P, Brunker P, Umana P (2006) The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem 281:5032-5036
22. Flores M, Desai DD, Downie M, Liang B, Reilly MP, McKenzie SE et al (2009) Dominant expression of the inhibitory FcgammaRIIB prevents antigen presentation by murine plasmacytoid dendritic cells. J Immunol 183:7129-7139
23. Fong DC, Brauweiler A, Minskoff SA, Bruhns P, Tamir I, Mellman I et al (2000) Mutational analysis reveals multiple distinct sites within Fc gamma receptor IIB that function in inhibitory signaling. J Immunol 165:4453-4462
24. French RR, Chan HT, Tutt AL, Glennie MJ (1999) CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 5:548-553
25. Galy AH, Spits H (1992) CD40 is functionally expressed on human thymic epithelial cells. J Immunol 149:775-782
26. Gieffers C, Kluge M, Merz C, Sykora J, Thiemann M, Schaal R et al (2013) APG350 induces superior clustering of TRAIL-Receptors and shows therapeutic anti-tumor efficacy independent of cross-linking via Fcgamma-Receptors. Mol Cancer Ther 12(12):2735-2747
27. Golay J, Da Roit F, Bologna L, Ferrara C, Leusen JH, Rambaldi A et al (2013) Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood 122:3482-3491
28. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L et al (2005) Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 174:817-826
29. Green SK, Karlsson MC, Ravetch JV, Kerbel RS (2002) Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer. Cancer Res 62:6891-6900
30. Ha SJ, Mueller SN, Wherry EJ, Barber DL, Aubert RD, Sharpe AH et al (2008) Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J Exp Med 205:543-555
31. Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF (2006) Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med 203:743-753
32. Hart DN, McKenzie JL (1988) Isolation and characterization of human tonsil dendritic cells. J Exp Med 168:157-170
33. Haynes NM, Hawkins ED, Li M, McLaughlin NM, Hammerling GJ, Schwendener R et al (2010) CD11c + dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors. J Immunol 185:532-541
34. He LZ, Prostak N, Thomas LJ, Vitale L, Weidlick J, Crocker A et al (2013) Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27- transgenic mice. J Immunol 191:4174-4183
35. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723
36. Jonsson F, Mancardi DA, Albanesi M, Bruhns P (2013) Neutrophils in local and systemic antibody-dependent inflammatory and anaphylactic reactions. J Leukoc Biol 94:643-656
37. Kaneko Y, Nimmerjahn F, Ravetch JV (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313:670-673
38. Kellner C, Derer S, Valerius T, Peipp M (2013) Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions. Methods 65(1):105-113
39. Law CL, Gordon KA, Collier J, Klussman K, McEarchern JA, Cerveny CG et al (2005) Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res 65:8331-8338
40. Lee CC, Cragg M, Glennie MJ, Johnson P (2012) Novel monoclonal antibody approaches to cancer immunotherapy. Br J Clin Pharmacol Li F, Ravetch JV (2013) Antitumor activities of agonistic anti-TNFR antibodies require differential FcgammaRIIB coengagement in vivo. Proc Natl Acad Sci U S A 110(48):19501-19506
41. Li F, Ravetch JV (2012) Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcgamma receptor engagement. Proc Natl Acad Sci U S A 109:10966-10971
42. Li F, Ravetch JV (2011) Inhibitory Fcgamma receptor engagement drives adjuvant and antitumor activities of agonistic CD40 antibodies. Science 333:1030-1034
43. Li X, Wu J, Carter RH, Edberg JC, Su K, Cooper GS et al (2003) A novel polymorphism in the Fcgamma receptor IIB (CD32B) transmembrane region alters receptor signaling. Arthritis Rheum 48:3242-3252
44. Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS (2010) Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 95:135-143
45. Lim SH, Vaughan AT, Ashton-Key M, Williams EL, Dixon SV, Chan CH et al (2011) Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 118(9):2530-2340
46. Liu YJ, Joshua DE, Williams GT, Smith CA, Gordon J, MacLennan IC (1989) Mechanism of antigen-driven selection in germinal centres. Nature 342:929-931
47. Mimoto F, Katada H, Kadono S, Igawa T, Kuramochi T, Muraoka M et al (2013) Engineered antibody Fc variant with selectively enhanced FcgammaRIIb binding over both FcgammaRIIa( R131) and FcgammaRIIa(H131). Protein Eng Des Sel 26:589-598
48. Minard-Colin V, Xiu Y, Poe JC, Horikawa M, Magro CM, Hamaguchi Y et al (2008) Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood 112:1205-1213
49. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S et al (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115:4393-4402
50. Muta T, Kurosaki T, Misulovin Z, Sanchez M, Nussenzweig MC, Ravetch JV (1994) A 13- amino-acid motif in the cytoplasmic domain of Fc gamma RIIB modulates B-cell receptor signalling. Nature 369:340
51. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV (2005) FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23:41-51
52. Nimmerjahn F, Ravetch JV (2007a) Antibodies, Fc receptors and cancer. Curr Opin Immunol 19:239-245
53. Nimmerjahn F, Ravetch JV (2005) Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310:1510-1512
54. Nimmerjahn F, Ravetch JV (2007b) Fc-receptors as regulators of immunity. Adv Immunol 96:179-204
55. Nimmerjahn F, Ravetch JV (2006) Fcgamma receptors: old friends and new family members. Immunity 24:19-28
56. Nunes J, Klasen S, Ragueneau M, Pavon C, Couez D, Mawas C et al (1993) CD28 mAbs with distinct binding properties differ in their ability to induce T cell activation: analysis of early and late activation events. Int Immunol 5:311-315
57. Oflazoglu E, Stone IJ, Brown L, Gordon KA, van Rooijen N, Jonas M et al (2009) Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40. Br J Cancer 100:113-117
58. Okada H, Bolland S, Hashimoto A, Kurosaki M, Kabuyama Y, Iino M et al (1998) Role of the inositol phosphatase SHIP in B cell receptor-induced Ca2 + oscillatory response. J Immunol 161:5129-5132
59. Ono M, Bolland S, Tempst P, Ravetch JV (1996) Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB. Nature 383:263-266
60. Palmer BE, Neff CP, Lecureux J, Ehler A, Dsouza M, Remling-Mulder L et al (2013) In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4 + T cell levels in humanized mice. J Immunol 190:211-219
61. Paulie S, Ehlin-Henriksson B, Mellstedt H, Koho H, Ben-Aissa H, Perlmann P (1985) A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes. Cancer Immunol Immunother 20:23-28
62. Paulie S, Rosen A, Ehlin-Henriksson B, Braesch-Andersen S, Jakobson E, Koho H et al (1989) The human B lymphocyte and carcinoma antigen, CDw40, is a phosphoprotein involved in growth signal transduction. J Immunol 142:590-595
63. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP (2009) Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti- CTLA-4 antibodies. J Exp Med 206:1717-1725
64. Phillips NE, Parker DC (1983) Fc-dependent inhibition of mouse B cell activation by whole antimu antibodies. J Immunol 130:602-606
65. Radstake TR, Franke B, Wenink MH, Nabbe KC, Coenen MJ, Welsing P et al (2006) The functional variant of the inhibitory Fcgamma receptor IIb (CD32B) is associated with the rate of radiologic joint damage and dendritic cell function in rheumatoid arthritis. Arthritis Rheum 54:3828-3837
66. Ravetch JV, Bolland S (2001) IgG Fc receptors. Annu Rev Immunol 19:275-290
67. Reichert JM, Dhimolea E (2012) The future of antibodies as cancer drugs. Drug Discov Today 17:954-63
68. Roberts DJ, Franklin NA, Kingeter LM, Yagita H, Tutt AL, Glennie MJ et al (2010) Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells. J Immunother 33:769-779
69. Roche (2013) FDA approves Roche's Gazyva (obinutuzumab) for people with previously untreated chronic lymphocytic leukemia (CLL). Press Release. http://www.roche.com/media/ media-releases/med-cor-2013-11-01.htm
70. Sato K, Ochi A (1998) Superclustering of B cell receptor and Fc gamma RIIB1 activates Src homology 2-containing protein tyrosine phosphatase-1. J Immunol 161:2716-2722
71. Schriever F, Freedman AS, Freeman G, Messner E, Lee G, Daley J et al (1989) Isolated human follicular dendritic cells display a unique antigenic phenotype. J Exp Med 169:2043-2058
72. Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, Korman AJ (2013) Anti-CTLA-4 Antibodies of IgG2a isotype enhance antitumour activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 1(1):32-42
73. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F et al (2013) Fcdependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti- CTLA-4 therapy against melanoma. J Exp Med 210:1695-1710
74. Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE et al (2004) Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 199:437-448
75. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454
76. Tutt AL, O'Brien L, Hussain A, Crowther GR, French RR, Glennie MJ (2002) T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J Immunol 168:2720-2728
77. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM et al (2004) The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199:1659-1669
78. Vaughan AT, Iriyama C, Beers SA, Chan CHT, Lim SH, Williams EL et al (2013) Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity. Blood 123(5): 669-677
79. Vitale LA, He LZ, Thomas LJ, Widger J, Weidlick J, Crocker A et al (2012) Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia. Clin Cancer Res 18:3812-3821
80. Vonderheide RH, Glennie MJ (2013) Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res 19:1035-43
81. Walshe CA, Beers SA, French RR, Chan CH, Johnson PW, Packham GK et al (2008) Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling. J Biol Chem 283:16971-16984
82. White AL, Chan HT, French RR, Beers SA, Cragg MS, Johnson PW et al (2013) FcgammaRIIB controls the potency of agonistic anti-TNFR mAbs. Cancer Immunol Immunother 62:941-948
83. White AL, Chan HTC, Roghanian A, French RR, Mockridge CI, Tutt AL et al (2011) Interaction with Fc gamma RIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol 187:1754-1763
84. White AL, Dou L, Chan HTC, Field VL, Mockridge CI, Moss K, Williams E, Butts C, Al- Shamkhani A, Cragg MS, Verbeek SJ, Johnson P, Glennie MJ, Beers SA (2014) FcR dependence of agonistic CD40 antibody is related to anatomical location and can be overcome by antibody multimerisation. J Immunology (in press)
85. Williams EL, Tutt AL, Beers SA, French RR, Chan CH, Cox KL et al (2013) Immunotherapy targeting inhibitory Fcgamma receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization. J Immunol 191:4130-4140
86. Williams EL, Tutt AL, French RR, Chan HT, Lau B, Penfold CA et al (2012) Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcgammaRIIB (CD32B). Eur J Immunol 42:2109-2120
87. Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D et al (2011) An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 19:101-113
88. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122-133
89. Xu Y, Szalai AJ, Zhou T, Zinn KR, Chaudhuri TR, Li X et al (2003) Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. J Immunol 171:562-568